logo
Plus   Neg
Share
Email

Hikma Pharma Completes FDA Response For Generic Advair Diskus

Hikma Pharmaceuticals Plc. (HIK.L, HKMPY.PK) said that it has submitted to the US Food and Drug Administration its response to deficiencies in its abbreviated new drug application for a generic version of GlaxoSmithKline's Advair Diskus.

Hikma initiated a clinical endpoint study in 2018, following receipt of a complete response letter from the FDA.

Siggi Olafsson, Chief Executive Officer of Hikma, said "We are confident in our ability to bring a generic version of Advair to the US market, which would enable us to improve patient access to this important medicine."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. National Restaurant Association is launching a campaign to help restaurants reassure customers that they stick to healthy and safe standards, as the restaurant industry is struggling amid the coronavirus outbreak. The association and its food and beverage safety training and certificate program ServSafe announced the nationwide "ServSafe Dining Commitment". Luxury electric car maker Tesla Inc. (TSLA) announced Thursday that it delivered about 90,650 vehicles in the second quarter of 2020, while producing more than 82,000 vehicles. The deliveries include 80,050 Model 3 sedans and Model Y cross-over SUVs as well as 10,600 Model S and X vehicles. The... Boy Scouts of America recalled about 78,000 units of Cub Scout outdoor activity pins for violating the federal lead content ban, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the activity pin's face and shaft contain levels of lead that exceed the federal lead content ban. Lead is toxic if ingested by young children and can cause adverse health issues.
Follow RTT